Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luciano Santollani

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Immunological Reviews|July 6, 2023
Spatiotemporally programming cytokine immunotherapies through protein engineeringLuciano Santollani, K Dane Wittrup
Soft Matter|October 19, 2016
Dynamic fluid-film interferometry as a predictor of bulk foam propertiesJohn M Frostad, Daniele Tammaro, Luciano Santollani, et al.
Mabs|August 4, 2022
An affinity threshold for maximum efficacy in anti-PD-1 immunotherapySarah C Cowles, Allison Sheen, Luciano Santollani, et al.
Molecular Cancer Therapeutics|October 9, 2024
Tumor Integrin-Targeted Glucose Oxidase Enzyme Promotes ROS-Mediated Cell Death that Combines with Interferon Alpha Therapy for Tumor ControlJordan A Stinson, Allison Sheen, Brianna M Lax, et al.
Nature Communications|March 1, 2024
CD8<sup>+</sup> T cell priming that is required for curative intratumorally anchored anti-4-1BB immunotherapy is constrained by TregsJoseph R Palmeri, Brianna M Lax, Joshua M Peters, et al.
Biorxiv : the Preprint Server for Biology|February 13, 2023
Tregs constrain CD8<sup>+</sup> T cell priming required for curative intratumorally anchored anti-4-1BB immunotherapyJoseph R Palmeri, Brianna M Lax, Joshua M Peters, et al.
Biorxiv : the Preprint Server for Biology|August 6, 2025
CD45 sequestration lowers the signaling threshold in lymphocytes and enhances anti-tumor immunityLauren Duhamel, Yiming J Zhang, William Pinney, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 24, 2023
Both intratumoral regulatory T cell depletion and CTLA-4 antagonism are required for maximum efficacy of anti-CTLA-4 antibodiesBrianna M Lax, Joseph R Palmeri, Emi A Lutz, et al.
Biorxiv : the Preprint Server for Biology|January 23, 2024
Local delivery of cell surface-targeted immunocytokines programs systemic anti-tumor immunityLuciano Santollani, Yiming J Zhang, Laura Maiorino, et al.
Nature Biomedical Engineering|January 11, 2022
Intratumourally injected alum-tethered cytokines elicit potent and safer local and systemic anticancer immunityYash Agarwal, Lauren E Milling, Jason Y H Chang, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Immunological Reviews|July 6, 2023
Spatiotemporally programming cytokine immunotherapies through protein engineeringLuciano Santollani, K Dane Wittrup
Soft Matter|October 19, 2016
Dynamic fluid-film interferometry as a predictor of bulk foam propertiesJohn M Frostad, Daniele Tammaro, Luciano Santollani, et al.
Mabs|August 4, 2022
An affinity threshold for maximum efficacy in anti-PD-1 immunotherapySarah C Cowles, Allison Sheen, Luciano Santollani, et al.
Molecular Cancer Therapeutics|October 9, 2024
Tumor Integrin-Targeted Glucose Oxidase Enzyme Promotes ROS-Mediated Cell Death that Combines with Interferon Alpha Therapy for Tumor ControlJordan A Stinson, Allison Sheen, Brianna M Lax, et al.
Nature Communications|March 1, 2024
CD8<sup>+</sup> T cell priming that is required for curative intratumorally anchored anti-4-1BB immunotherapy is constrained by TregsJoseph R Palmeri, Brianna M Lax, Joshua M Peters, et al.
Biorxiv : the Preprint Server for Biology|February 13, 2023
Tregs constrain CD8<sup>+</sup> T cell priming required for curative intratumorally anchored anti-4-1BB immunotherapyJoseph R Palmeri, Brianna M Lax, Joshua M Peters, et al.
Biorxiv : the Preprint Server for Biology|August 6, 2025
CD45 sequestration lowers the signaling threshold in lymphocytes and enhances anti-tumor immunityLauren Duhamel, Yiming J Zhang, William Pinney, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 24, 2023
Both intratumoral regulatory T cell depletion and CTLA-4 antagonism are required for maximum efficacy of anti-CTLA-4 antibodiesBrianna M Lax, Joseph R Palmeri, Emi A Lutz, et al.
Biorxiv : the Preprint Server for Biology|January 23, 2024
Local delivery of cell surface-targeted immunocytokines programs systemic anti-tumor immunityLuciano Santollani, Yiming J Zhang, Laura Maiorino, et al.
Nature Biomedical Engineering|January 11, 2022
Intratumourally injected alum-tethered cytokines elicit potent and safer local and systemic anticancer immunityYash Agarwal, Lauren E Milling, Jason Y H Chang, et al.
Pageof 2